We read with great interest the manuscript by Mazzaferro et al1 entitled “Metroticket 2.0 Model for Analysis of Competing Risks of Death Following Liver Transplantation for Hepatocellular Carcinoma.” The authors established a preoperatively assessed metric specific to “hepatocellular carcinoma (HCC)-related mortality” after liver transplantation (LT) for HCC using 1018 patients from three Italian centers followed by validation in 341 patients from Shanghai, China. The model was described as an improvement over past work and the authors concluded that their model, “could update current recommendations for cirrhotic patients with HCC.” Although the authors should be congratulated on a substantial effort and nuanced approach, we feel several points warrant emphasis to place their work in proper context.